12:00 AM
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Indacaterol/glycopyrronium bromide regulatory update

Novartis submitted a regulatory application to Japan's Ministry of Health, Labor and Welfare (MHLW) for QVA149 to treat chronic obstructive pulmonary disease (COPD). QVA149 is a fixed-dose combination of glycopyrronium bromide ( NVA237), an inhaled long-acting muscarinic receptor antagonist (LAMA), and indacaterol, a long-acting adrenergic...

Read the full 229 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >